TY - JOUR
T1 - Comparison of two total body irradiation regimens in allogeneic bone marrow transplantation for acute non-lymphoblastic leukemia in first remission
AU - Kim, Tae H.
AU - McGlave, Philip B.
AU - Ramsay, Norma
AU - Woods, William
AU - Bostrom, Bruce
AU - Vercellotti, Gregory
AU - Hurd, David
AU - Krivit, William
AU - Nesbit, Mark
AU - Haake, Robert
AU - Khan, Faiz
AU - Kersey, John H.
N1 - Funding Information:
.4cknow/eclgPment-Supported in part by a grant from the National Cancer Institute (POl-CA21737) and Children’s Cancer Research Fund. Dr. John Kersey is the recipient of an Outstanding Investigator Award (CA49721) from the National Cancer Institute. Accepted for publication 26 April 1990.
PY - 1990/10
Y1 - 1990/10
N2 - Between November 1976 and December 1987, 84 patients with newly diagnosed acute non-lymphoblastic leukemia who had achieved complete remission underwent non T-cell depleted allogeneic bone marrow transplantation from Human Leukocyte Antigen-Mixed Lymphocyte Culture (HLA-MLC) matched sibling donors. The first 36 patients (November 1976-June 1983) were prepared with cyclophosphamide sibling donors. The first 36 patients fraction total body irradiation with 750 cGy at a dose rate of 26 cGy/minute (Group I). The next 48 patients (July 1983-December 1987) were prepared with similar chemotherapy, but received hyperfractionated total body irradiation with total 1320 cGy, 165 cGy twice a day at a dose rate of 10 cGy/minute (Group II). Patient characteristics between these two groups are similar except for the significantly older age distribution in Group II. Median follow-up of Groups I and II are 8 years and 11 months and 2 years and 3 months, respectively. The Kaplan-Meier relapse-free survival, survival, and relapse rates at 3 years are 56, 58, and 19% in Group I and 69 (p = 0.22), 77 (p = 0.07), and 10% (p = 0.37) in Group II. There is no difference in the incidence of interstitial pneumonitis, viral or idiopathic, engraftment rate, or incidence of graft versus host disease (GVHD) between these two groups. The fractionated total body irradiation treated group had significantly less nausea and vomiting. Multivariate analysis shows that total body irradiation regimen is not a significant factor in regard to relapse rate, relapse-free survival, and survival.
AB - Between November 1976 and December 1987, 84 patients with newly diagnosed acute non-lymphoblastic leukemia who had achieved complete remission underwent non T-cell depleted allogeneic bone marrow transplantation from Human Leukocyte Antigen-Mixed Lymphocyte Culture (HLA-MLC) matched sibling donors. The first 36 patients (November 1976-June 1983) were prepared with cyclophosphamide sibling donors. The first 36 patients fraction total body irradiation with 750 cGy at a dose rate of 26 cGy/minute (Group I). The next 48 patients (July 1983-December 1987) were prepared with similar chemotherapy, but received hyperfractionated total body irradiation with total 1320 cGy, 165 cGy twice a day at a dose rate of 10 cGy/minute (Group II). Patient characteristics between these two groups are similar except for the significantly older age distribution in Group II. Median follow-up of Groups I and II are 8 years and 11 months and 2 years and 3 months, respectively. The Kaplan-Meier relapse-free survival, survival, and relapse rates at 3 years are 56, 58, and 19% in Group I and 69 (p = 0.22), 77 (p = 0.07), and 10% (p = 0.37) in Group II. There is no difference in the incidence of interstitial pneumonitis, viral or idiopathic, engraftment rate, or incidence of graft versus host disease (GVHD) between these two groups. The fractionated total body irradiation treated group had significantly less nausea and vomiting. Multivariate analysis shows that total body irradiation regimen is not a significant factor in regard to relapse rate, relapse-free survival, and survival.
KW - Bone marrow transplantation
KW - Total body irradiation
UR - http://www.scopus.com/inward/record.url?scp=0025083550&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025083550&partnerID=8YFLogxK
U2 - 10.1016/0360-3016(90)90009-9
DO - 10.1016/0360-3016(90)90009-9
M3 - Article
C2 - 2211256
AN - SCOPUS:0025083550
SN - 0360-3016
VL - 19
SP - 889
EP - 897
JO - International Journal of Radiation Oncology, Biology, Physics
JF - International Journal of Radiation Oncology, Biology, Physics
IS - 4
ER -